JP2018535972A5 - - Google Patents

Download PDF

Info

Publication number
JP2018535972A5
JP2018535972A5 JP2018522651A JP2018522651A JP2018535972A5 JP 2018535972 A5 JP2018535972 A5 JP 2018535972A5 JP 2018522651 A JP2018522651 A JP 2018522651A JP 2018522651 A JP2018522651 A JP 2018522651A JP 2018535972 A5 JP2018535972 A5 JP 2018535972A5
Authority
JP
Japan
Prior art keywords
amino acid
naturally encoded
encoded amino
antibody
molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018522651A
Other languages
English (en)
Japanese (ja)
Other versions
JP6931649B2 (ja
JP2018535972A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/060087 external-priority patent/WO2017079272A2/en
Publication of JP2018535972A publication Critical patent/JP2018535972A/ja
Publication of JP2018535972A5 publication Critical patent/JP2018535972A5/ja
Priority to JP2021132397A priority Critical patent/JP7220755B2/ja
Application granted granted Critical
Publication of JP6931649B2 publication Critical patent/JP6931649B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018522651A 2015-11-03 2016-11-02 新規な抗cd3抗体およびその使用 Active JP6931649B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021132397A JP7220755B2 (ja) 2015-11-03 2021-08-16 新規な抗cd3抗体およびその使用

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562250451P 2015-11-03 2015-11-03
US62/250,451 2015-11-03
US201562267086P 2015-12-14 2015-12-14
US62/267,086 2015-12-14
US201662374693P 2016-08-12 2016-08-12
US62/374,693 2016-08-12
PCT/US2016/060087 WO2017079272A2 (en) 2015-11-03 2016-11-02 Anti-cd3-folate conjugates and their uses

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021132397A Division JP7220755B2 (ja) 2015-11-03 2021-08-16 新規な抗cd3抗体およびその使用

Publications (3)

Publication Number Publication Date
JP2018535972A JP2018535972A (ja) 2018-12-06
JP2018535972A5 true JP2018535972A5 (cg-RX-API-DMAC7.html) 2019-12-12
JP6931649B2 JP6931649B2 (ja) 2021-09-08

Family

ID=58662682

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018522651A Active JP6931649B2 (ja) 2015-11-03 2016-11-02 新規な抗cd3抗体およびその使用
JP2021132397A Active JP7220755B2 (ja) 2015-11-03 2021-08-16 新規な抗cd3抗体およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021132397A Active JP7220755B2 (ja) 2015-11-03 2021-08-16 新規な抗cd3抗体およびその使用

Country Status (13)

Country Link
US (2) US11851488B2 (cg-RX-API-DMAC7.html)
EP (1) EP3370771A4 (cg-RX-API-DMAC7.html)
JP (2) JP6931649B2 (cg-RX-API-DMAC7.html)
KR (1) KR20180077271A (cg-RX-API-DMAC7.html)
CN (1) CN108348603B (cg-RX-API-DMAC7.html)
AU (1) AU2016349786C1 (cg-RX-API-DMAC7.html)
BR (1) BR112018009004A8 (cg-RX-API-DMAC7.html)
CA (1) CA3002573A1 (cg-RX-API-DMAC7.html)
IL (1) IL258759B2 (cg-RX-API-DMAC7.html)
MX (1) MX2018005232A (cg-RX-API-DMAC7.html)
NZ (1) NZ743049A (cg-RX-API-DMAC7.html)
SG (2) SG10201913746RA (cg-RX-API-DMAC7.html)
WO (1) WO2017079272A2 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019103981A1 (en) * 2017-11-22 2019-05-31 Geltor Inc. Methods and systems for engineering collagen
EP3844188A1 (en) 2018-08-28 2021-07-07 Ambrx, Inc. Anti-cd3 antibody folate bioconjugates and their uses
KR102239781B1 (ko) * 2019-04-08 2021-04-13 주식회사 녹십자 Gpnmb 및 cd3에 특이적으로 결합하는 이중특이적 항체 및 이의 용도
US20200392230A1 (en) * 2019-05-14 2020-12-17 Qlb Biotherapeutics Bispecific anti-cd3 x cd20 antibodies and uses thereof
KR102878895B1 (ko) 2019-05-21 2025-10-31 노파르티스 아게 Cd19 결합 분자 및 이의 용도
TWI888487B (zh) * 2020-02-14 2025-07-01 日商協和麒麟股份有限公司 與cd3結合之雙特異性抗體
TWI827807B (zh) * 2020-02-26 2024-01-01 香港商潤俊(中國)有限公司 抗cd3抗體葉酸生物共軛物及其用途
WO2021173889A1 (en) 2020-02-26 2021-09-02 Ambrx, Inc. Uses of anti-cd3 antibody folate bioconjugates
BR112023003366A2 (pt) 2020-08-25 2023-05-09 Gilead Sciences Inc Moléculas multiespecíficas de ligação ao antígeno que têm como alvo hiv e métodos de uso

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
FR2504010B1 (fr) 1981-04-15 1985-10-25 Sanofi Sa Medicaments anticancereux contenant la chaine a de la ricine associee a un anticorps antimelanome et procede pour leur preparation
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US4589071A (en) 1982-04-19 1986-05-13 Nissan Motor Co., Ltd. Method and apparatus for controlling reduction ratio of continuously variable transmission with acceleration compensation
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
US4625014A (en) 1984-07-10 1986-11-25 Dana-Farber Cancer Institute, Inc. Cell-delivery agent
US4542225A (en) 1984-08-29 1985-09-17 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
US4659839A (en) 1984-10-10 1987-04-21 Mallinckrodt, Inc. Coupling agents for radiolabeled antibody fragments
CA1336076C (en) 1985-01-14 1995-06-27 Alan R. Fritzberg Metal radionuclide labeled proteins for diagnosis and therapy
US4680338A (en) 1985-10-17 1987-07-14 Immunomedics, Inc. Bifunctional linker
US4699784A (en) 1986-02-25 1987-10-13 Center For Molecular Medicine & Immunology Tumoricidal methotrexate-antibody conjugate
US4904584A (en) 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
ES2252732T3 (es) 1992-05-26 2006-05-16 Immunex Corporation Nueva citoquina que une cd30.
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
WO1997034631A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
US6608183B1 (en) 1997-07-14 2003-08-19 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins
US6451986B1 (en) 1998-06-22 2002-09-17 Immunex Corporation Site specific protein modification
ES2289824T3 (es) 1998-10-30 2008-02-01 Novozymes A/S Proteinas glicosiladas con alergenicidad reducida.
ES2346646T5 (es) 2002-05-30 2018-02-15 The Scripps Research Institute Ligación catalizada con cobre de azidas y acetilenos
EP1613735B1 (en) * 2003-04-17 2012-01-25 The Scripps Research Institute Expanding the eukaryotic genetic code
EP1636340A4 (en) 2003-06-18 2009-02-11 Scripps Research Inst COMPLEMENTS TO THE GENETIC CODE OF UNNATURATIVE REACTIVE AMINO ACIDS
GB0716160D0 (en) 2007-08-17 2007-09-26 Biotransformations Ltd Materials and methods for treating cancers which express folate receptors
JP2012034668A (ja) 2010-08-12 2012-02-23 Tohoku Univ ヒト型化抗egfr抗体リジン置換可変領域断片及びその利用
JP6400470B2 (ja) 2011-05-16 2018-10-03 ジェネロン(シャンハイ)コーポレイション リミテッド 多重特異性Fab融合タンパク質および使用法
CN107722124A (zh) * 2011-05-21 2018-02-23 宏观基因有限公司 能够与人和非人cd3结合的cd3结合分子
HUE033245T2 (hu) * 2011-12-19 2017-11-28 Synimmune Gmbh Bispecifikus ellenanyag molekula
US10968276B2 (en) 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
JP2016531100A (ja) * 2013-07-12 2016-10-06 ザイムワークス,インコーポレイテッド 二重特異的なcd3及びcd19抗原結合構築物
EP2840091A1 (en) 2013-08-23 2015-02-25 MacroGenics, Inc. Bi-specific diabodies that are capable of binding gpA33 and CD3 and uses thereof
AU2015292406B2 (en) * 2014-07-25 2021-03-11 Cytomx Therapeutics, Inc Anti-CD3 antibodies, activatable anti-CD3 antibodies, multispecific anti-CD3 antibodies, multispecific activatable anti-CD3 antibodies, and methods of using the same
JP2018534933A (ja) * 2015-11-02 2018-11-29 ヤンセン ファーマシューティカ エヌ.ベー. 抗il1rap抗体、il1rapとcd3を結合する二重特異性抗原結合分子、及びその使用
AU2019255270A1 (en) * 2018-04-17 2020-11-19 Invenra Inc. Trivalent trispecific antibody constructs
EP3844188A1 (en) * 2018-08-28 2021-07-07 Ambrx, Inc. Anti-cd3 antibody folate bioconjugates and their uses
CN113660957B (zh) * 2019-02-12 2024-12-13 Ambrx公司 包含抗体-tlr激动剂缀合物的组合物、方法和用途
CN116178547A (zh) * 2019-02-22 2023-05-30 武汉友芝友生物制药股份有限公司 Cd3抗原结合片段及其应用

Similar Documents

Publication Publication Date Title
JP2018535972A5 (cg-RX-API-DMAC7.html)
JP2019033743A5 (cg-RX-API-DMAC7.html)
US20240100129A1 (en) Serum Albumin-Binding Fibronectin Type III Domains
ES2885815T3 (es) Nuevo formato biespecífico adecuado para su uso en el cribado de alto rendimiento
JP2015509097A5 (cg-RX-API-DMAC7.html)
ES2967739T3 (es) Formato de anticuerpo heterodimérico multiespecífico dirigido al menos a CD3 y a HSA
JP2017529067A5 (cg-RX-API-DMAC7.html)
JP2017529097A5 (cg-RX-API-DMAC7.html)
JP2016536322A5 (cg-RX-API-DMAC7.html)
RU2016151265A (ru) Антитела, направленные на cd127
ES2822431T3 (es) Polipéptidos de unión a IL-17A
JP2013506411A5 (cg-RX-API-DMAC7.html)
CN102906112A (zh) Trail r2-特异性多聚体支架
RU2015100656A (ru) Способ получения конъюгатов fc-фрагмента антитела, включающих по меньшей мере одну связывающую группировку, которая специфически связывается с мишенью, и их применения
JP2010535032A5 (cg-RX-API-DMAC7.html)
JP2014505463A5 (cg-RX-API-DMAC7.html)
JP2011501951A5 (cg-RX-API-DMAC7.html)
JP2016533174A5 (cg-RX-API-DMAC7.html)
RU2018141360A (ru) Contorsbody - одноцепочечный связывающий мишень агент
JP2013529080A5 (cg-RX-API-DMAC7.html)
JP2017529870A5 (cg-RX-API-DMAC7.html)
JP2017523781A5 (cg-RX-API-DMAC7.html)
JP2008515889A5 (cg-RX-API-DMAC7.html)
JP2017534296A5 (cg-RX-API-DMAC7.html)
JP2019505565A5 (cg-RX-API-DMAC7.html)